New injection tested to calm transplant rejection when steroids fail
NCT ID NCT01366092
Summary
This study tested a daily low-dose injection of a drug called IL-2 for people with chronic graft-versus-host disease (cGVHD) who did not respond well to standard steroid treatment. The goal was to see if adding IL-2 could help control the condition and allow doctors to reduce steroid doses. Participants gave themselves the injection daily for 12 weeks while researchers monitored their symptoms and immune system response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT VERSUS HOST DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02214, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States
Conditions
Explore the condition pages connected to this study.